Hylomorph is a cutting-edge Medtech Startup company and spin-off of the Swiss Federal Institute of Technology. We specialize in developing innovative biomaterials for healthcare products by combining micro-engineering and biotechnology. Our core technology focuses on optimizing the interface between implantable medical devices and biological tissues.

Located at Technopark Zurich, in the heart of Switzerland, our headquarters serve as a hub for our groundbreaking research and development. With a team of highly skilled professionals, including our CEO Dr. Simone Bottan, we are dedicated to pushing the boundaries of medical technology.

At Hylomorph, we offer two flagship products: the HyloMate Pouch and the HyloMate Sheet. These products utilize our biocompatible membrane technology, which is based on microstructured biosynthesized cellulose. This technology ensures superior performance, safety, and compatibility with the human body.

Driven by innovation and backed by awards and support from the Horizon 2020 program of the European Union, Hylomorph is committed to revolutionizing the healthcare industry by delivering cutting-edge solutions for patients and medical professionals alike